Outcomes and Costs of COVID-19 mAb Prophylaxis Among Unvaccinated Household Contacts in the US | Infectious Diseases | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Estimated Health Outcomes and Costs of COVID-19 Prophylaxis With Monoclonal Antibodies Among Unvaccinated Household Contacts in the US

Educational Objective
To identify the key insights or developments described in this article
1 Credit CME
Key Points

Question  What are the potential health outcomes and costs of SARS-CoV-2 monoclonal antibody postexposure prophylaxis (PEP) for household contacts of people with COVID-19 in the US?

Findings  In this decision analytical model study, for a month with transmission intensity similar to that of May 2021, a monoclonal antibody PEP program reaching 50% of exposed, unvaccinated household members aged 50 years and older was estimated to avert 528 hospitalizations and 84 deaths in a low-transmission scenario and 1404 hospitalizations and 223 deaths in a high-transmission scenario. The program was also estimated to be cost saving to payers in the high-transmission scenario as a result of averted hospitalizations.

Meaning  These findings suggest that COVID-19 PEP with monoclonal antibodies may be associated with reduced costs and improved population health.

Abstract

Importance  The COVID-19 pandemic has led to more than 900 000 deaths in the US and continues to disrupt lives even as effective vaccines are available.

Objective  To estimate the health outcomes and net cost of implementing postexposure prophylaxis (PEP) with monoclonal antibodies (mAbs) against household exposure to COVID-19.

Design, Setting, and Participants  This study is a decision analytical model of results from a randomized clinical trial of casirivimab with imdevimab administered as subcutaneous injections to unvaccinated, SARS-CoV-2–negative household contacts of people with confirmed COVID-19 with complementary data on household demographic structure, vaccine coverage, and confirmed COVID-19 case counts. The study used US data from May 2021 for a simulated population of US individuals of all ages within low-transmission or high-transmission scenarios.

Exposures  Age, sex, race, ethnicity, and COVID-19 vaccination status.

Main Outcome or Measures  Symptomatic infection, hospitalization, death, and net payer cost of monoclonal antibody PEP for COVID-19.

Results  In a month of transmission intensity similar to that of May 2021, a mAb PEP program reaching 50% of exposed, unvaccinated household members aged 50 years and older was estimated to avert 1820 symptomatic infections (95% uncertainty interval [UI], 1220-2454 symptomatic infections), 528 hospitalizations (95% UI, 354-724 hospitalizations), and 84 deaths (95% UI, 55-116 deaths) in a low-transmission scenario and 4834 symptomatic infections (95% UI, 3375-6257 symptomatic infections), 1404 hospitalizations (95% UI, 974-1827 hospitalizations), and 223 deaths (95% UI, 152-299 deaths) in a high-transmission scenario. Without mAb PEP, the estimated cost of hospitalizations due to COVID-19 infections from household exposure in the lower transmission scenario was $149 million (95% UI, $115-$196 million), whereas the estimated hospitalization cost in the higher transmission scenario was $400 million (95% UI, $312-$508 million). In the lower transmission scenario, mAb PEP administered to 50% of eligible contacts aged 80 years and older was estimated to have 82% probability of saving costs, but was not associated with cost savings at age thresholds of 50 years and older or 20 years and older. In contrast, in the high-transmission scenario, mAb PEP administered to 50% of eligible household contacts had estimated cost savings in 100% of simulations at the 80-year age threshold, 96% of simulations at the 50-year threshold, and 2% of simulations at the 20-year thresholds.

Conclusions and Relevance  In this modeling study of a simulated US population, a mAb PEP for COVID-19 program was estimated to improve health outcomes and reduce costs. In the setting of a susceptible variant of SARS-CoV-2, health system and public health actors would have an opportunity to improve health and reduce net payer costs through COVID-19 PEP with mAbs.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Accepted for Publication: March 7, 2022.

Published: April 22, 2022. doi:10.1001/jamanetworkopen.2022.8632

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2022 Flaxman AD et al. JAMA Network Open.

Corresponding Author: Jennifer M. Ross, MD, International Clinical Research Center, Department of Global Health, University of Washington, HMC Box #359927, 325 9th Ave, Seattle, WA 98104 (jross3@uw.edu).

Author Contributions: Dr Flaxman had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Flaxman, Barnabas, Ross.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Flaxman, Issema, Ross.

Critical revision of the manuscript for important intellectual content: Flaxman, Barnabas, Ross.

Statistical analysis: Flaxman, Issema.

Administrative, technical, or material support: Barnabas.

Supervision: Barnabas, Ross.

Conflict of Interest Disclosures: Dr Flaxman reported consulting for Janssen, SwissRe, Merck for Mothers, Sanofi, and Agathos, Ltd. Dr Barnabas reported receiving support from Regeneron Pharmaceutical for writing a conference abstract and a manuscript outside the submitted work. No other disclosures were reported.

Funding/Support: This work was supported by funding from the National Science Foundation (award DMS-1839116).

Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

References
1.
Dong  E , Du  H , Gardner  L .  An interactive web-based dashboard to track COVID-19 in real time.   Lancet Infect Dis. 2020;20(5):533-534. doi:10.1016/S1473-3099(20)30120-1PubMedGoogle ScholarCrossref
2.
Diesel  J , Sterrett  N , Dasgupta  S ,  et al.  COVID-19 vaccination coverage among adults: United States, December 14, 2020-May 22, 2021.   MMWR Morb Mortal Wkly Rep. 2021;70(25):922-927. doi:10.15585/mmwr.mm7025e1PubMedGoogle ScholarCrossref
3.
Pei  S , Kandula  S , Shaman  J .  Differential effects of intervention timing on COVID-19 spread in the United States.   Sci Adv. 2020;6(49):eabd6370. doi:10.1126/sciadv.abd6370PubMedGoogle ScholarCrossref
4.
Monod  M , Blenkinsop  A , Xi  X ,  et al; Imperial College COVID-19 Response Team.  Age groups that sustain resurging COVID-19 epidemics in the United States.   Science. 2021;371(6536):eabe8372. doi:10.1126/science.abe8372PubMedGoogle ScholarCrossref
5.
Baden  LR , El Sahly  HM , Essink  B ,  et al; COVE Study Group.  Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine.   N Engl J Med. 2021;384(5):403-416. doi:10.1056/NEJMoa2035389PubMedGoogle ScholarCrossref
6.
Polack  FP , Thomas  SJ , Kitchin  N ,  et al; C4591001 Clinical Trial Group.  Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine.   N Engl J Med. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577PubMedGoogle ScholarCrossref
7.
Goldman  JD , Lye  DCB , Hui  DS ,  et al; GS-US-540-5773 Investigators.  Remdesivir for 5 or 10 days in patients with severe Covid-19.   N Engl J Med. 2020;383(19):1827-1837. doi:10.1056/NEJMoa2015301PubMedGoogle ScholarCrossref
8.
Hamel  L , Lopes  L , Kearney  A , Sparks  G , Stokes  M , Brodie  M . KFF COVID-19 vaccine monitor: June 2021. June 30, 2021. Accessed March 21, 2022. https://www.kff.org/coronavirus-covid-19/poll-finding/kff-covid-19-vaccine-monitor-june-2021/
9.
Nanduri  S , Pilishvili  T , Derado  G ,  et al.  Effectiveness of Pfizer-BioNTech and Moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B.1.617.2 (Delta) variant: National Healthcare Safety Network, March 1-August 1, 2021.   MMWR Morb Mortal Wkly Rep. 2021;70(34):1163-1166. doi:10.15585/mmwr.mm7034e3PubMedGoogle ScholarCrossref
10.
Ferdinands  JM , Rao  S , Dixon  BE ,  et al.  Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance: VISION Network, 10 States, August 2021-January 2022.   MMWR Morb Mortal Wkly Rep. 2022;71(7):255-263. doi:10.15585/mmwr.mm7107e2PubMedGoogle ScholarCrossref
11.
O’Brien  MP , Forleo-Neto  E , Musser  BJ ,  et al; Covid-19 Phase 3 Prevention Trial Team.  Subcutaneous REGEN-COV antibody combination to prevent Covid-19.   N Engl J Med. 2021;385(13):1184-1195. doi:10.1056/NEJMoa2109682PubMedGoogle ScholarCrossref
12.
Cohen  MS , Nirula  A , Mulligan  MJ ,  et al; BLAZE-2 Investigators.  Effect of bamlanivimab vs placebo on incidence of COVID-19 among residents and staff of skilled nursing and assisted living facilities: a randomized clinical trial.   JAMA. 2021;326(1):46-55. doi:10.1001/jama.2021.8828PubMedGoogle ScholarCrossref
13.
Casadevall  A , Pirofski  LA , Joyner  MJ .  The principles of antibody therapy for infectious diseases with relevance for COVID-19.   mBio. 2021;12(2):e03372-20. doi:10.1128/mBio.03372-20PubMedGoogle ScholarCrossref
14.
Taylor  PC , Adams  AC , Hufford  MM , de la Torre  I , Winthrop  K , Gottlieb  RL .  Neutralizing monoclonal antibodies for treatment of COVID-19.   Nat Rev Immunol. 2021;21(6):382-393. doi:10.1038/s41577-021-00542-xPubMedGoogle ScholarCrossref
15.
US Food and Drug Administration. FDA authorizes REGEN-COV monoclonal antibody therapy for post-exposure prophylaxis (prevention) for COVID-19. August 10, 2021. Accessed March 21, 2022. https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-regen-cov-monoclonal-antibody-therapy-post-exposure-prophylaxis-prevention-covid-19
16.
VanBlargan  LA , Errico  JM , Halfmann  PJ ,  et al.  An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies.   Nat Med. 2022;28:490-495. doi:10.1038/s41591-021-01678-yPubMedGoogle ScholarCrossref
17.
US Food and Drug Administration. Letter of authorization for emergency use of REGEN-CoV reissue. January 24, 2022. Accessed February 11, 2022. https://www.fda.gov/media/145610/download
18.
Park  YJ , De Marco  A , Starr  TN ,  et al.  Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry.   Science. 2022;375(6579):449-454. doi:10.1126/science.abm8143PubMedGoogle ScholarCrossref
19.
US Census Bureau. 2019 American Community Survey public use microdata samples (PUMS). Accessed March 21, 2022. https://www.census.gov/programs-surveys/acs/microdata.html
20.
Husereau  D , Drummond  M , Petrou  S ,  et al; ISPOR Health Economic Evaluation Publication Guidelines-CHEERS Good Reporting Practices Task Force.  Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.   Value Health. 2013;16(2):231-250. doi:10.1016/j.jval.2013.02.002PubMedGoogle ScholarCrossref
21.
Flaxman  AD , Issema  R . Health impact and cost of COVID-19 prophylaxis with monoclonal antibodies. August 31, 2021. Accessed March 21, 2022. https://zenodo.org/record/5338920#.Yjor_-fMI2w
22.
University of Washington Office of Research. Worksheet: human subjects determination version 2.5. 2021. Accessed February 28, 2022. https://www.washington.edu/research/forms-and-templates/worksheet-human-subjects-research/
23.
Thompson  HA , Mousa  A , Dighe  A ,  et al.  Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) setting-specific transmission rates: a systematic review and meta-analysis.   Clin Infect Dis. 2021;73(3):e754-e764. doi:10.1093/cid/ciab100PubMedGoogle ScholarCrossref
24.
Efron  B .  Bootstrap methods: another look at the jackknife.   Ann Stat. 1979;7(1):1-26. doi:10.1214/aos/1176344552Google ScholarCrossref
25.
Centers for Disease Control and Prevention Case Surveillance Task Force. COVID-19 case surveillance public use data. Accessed June 1, 2021. https://dev.socrata.com/foundry/data.cdc.gov/vbim-akqf
26.
Thompson  MG , Burgess  JL , Naleway  AL ,  et al.  Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers: eight U.S. locations, December 2020-March 2021.   MMWR Morb Mortal Wkly Rep. 2021;70(13):495-500. doi:10.15585/mmwr.mm7013e3PubMedGoogle ScholarCrossref
27.
FAIR Health. Costs for a hospital stay for COVID-19. April 23, 2020. Accessed July 27, 2021. https://www.fairhealth.org/article/costs-for-a-hospital-stay-for-covid-19
28.
Regeneron Pharmaceuticals. REGENERON announces new U.S. government agreement to purchase additional doses of REGEN-COVTM (casirivimab and imdevimab) antibody cocktail. September 14, 2021. Accessed January 20, 2022. https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-new-us-government-agreement-purchase
29.
Centers for Medicare & Medicaid Services. Monoclonal antibody COVID-19 infusion. Accessed January 24, 2022. https://www.cms.gov/medicare/covid-19/monoclonal-antibody-covid-19-infusion
30.
Haidar  G , Mellors  JW .  Improving the outcomes of immunocompromised patients with COVID-19.   Clin Infect Dis. 2021;73(6):e1397-e1401. doi:10.1093/cid/ciab397PubMedGoogle ScholarCrossref
31.
National Institutes of Health COVID-19 Treatment Guidelines Panel. Updated COVID-19 Treatment Guidelines Panel’s statement on the prioritization of anti-SARS-CoV-2 monoclonal antibodies for the treatment or prevention of SARS-CoV-2 infection when there are logistical or supply constraints. October 7, 2021. Accessed January 21, 2022. https://files.covid19treatmentguidelines.nih.gov/guidelines/archive/updated-statement-on-the-prio-10-07-2021.pdf
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close